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Abstract
Background: Notochordal cell conditioned medium (NCCM) derived from non-chondrodystrophic dogs has
pro-anabolic and anti-catabolic effects upon nucleus pulposus (NP) cells. Here, for the first time, we assessed the
ability of NCCM to influence the production of extracellular matrix and inflammatory proteins by healthy and
osteoarthritic human chondrocytes within engineered cartilage tissues. We hypothesized that, similar to its action
on NP cells, NCCM exerts metabolic and anti-catabolic effects on human articular chondrocytes and has the
potential to significantly counteract inflammatory mediators.
Methods: Chondrocytes from nine non-osteoarthritic patients and from six osteoarthritic (OA) donors at the time of
total knee arthroplasty were chondro-differentiated in pellets for 2 weeks. Non-OA pellets were exposed for 72 hours to
IL-1β/TNF-α and then cultured up to 14 days in 2 % FBS-supplemented NCCM or 2 % FBS-supplemented medium
(control (ctr)). OA pellets were cultured in NCCM or ctr medium without pro-inflammatory treatment. Tissues after each
culture phase were analyzed biochemically (GAG/DNA), (immuno-) histologically (collagen I, II and GAG) and by
Western blotting. Supernatants were analyzed by ELISA.
Results: Response to NCCM was age and disease dependent with healthy chondrocyte pellets (from donors >55 years
of age) recovering their glycosaminoglycan (GAG) contents to baseline levels only with NCCM. OA pellets treated with
NCCM significantly increased GAG content (1.8-fold) and levels of hyaluronic acid link protein (HAPLN), fibromodulin
and SOX-9. The catabolic proteins (matrix metalloproteinase (MMP)-3 and MMP-13) and pro-inflammatory enzyme
levels (cyclooxygenase-2 (COX-2)) were markedly reduced and there was significantly reduced secretion of
pro-inflammatory chemokines (IL-6 and IL-8).
Conclusions: NCCM restores cartilage matrix production of end-stage human OA chondrocytes towards a healthy
phenotype and suppresses the production of inflammatory mediators. Harnessing the necessary and sufficient factors
within NCCM that confers chondroprotection and regenerative effects could lead to a minimally invasive agent for
treatment of degenerative and inflammatory joint diseases.
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Background
Osteoarthritis (OA) is not only the most common joint
disease worldwide causing pain and functional limita-
tions, but it can also lead to worsening of co-
morbidities, such as diabetes and cardiovascular disease,
due to reduced activity [1, 2]. OA, in particular of the
knee joint, already generates annual costs of US$185 bil-
lion in the USA and due to demographic changes the
costs associated with OA are predicted to increase in the
future, necessitating the development of novel, disease-
modifying interventions [3–5].
Beyond physical therapy modalities, anti-inflammatory
medications, and intra-articular injections there are no
other effective treatments currently available for OA
apart from (for end-stage OA) joint arthroplasty. The
quest for an effective disease-modifying osteoarthritic
agent/drug (DMOAD) is an area of intense investigation
worldwide that could be enabled by studying degenera-
tive joint diseases sharing many features with OA, such
as degenerative disc disease (DDD). DDD, like OA, in-
volves an avascular, ischemic and hypoxic niche, the loss
of extracellular matrix homeostasis, progressive cell
death, and the development of a pro-catabolic, pro-
inflammatory state with impaired cellular repair and
known propensity for chronic pain [6].
Adult nucleus pulposus (NP) cells are commonly re-
ferred to as “chondrocyte-like cells”, given their similar-
ities in extracellular matrix (ECM) production, cell size,
and the hypoxic, ischemic environment within which
they reside, even though there are differences in the ex-
pression of certain ECM molecules [7, 8]. Consistent
with its participation in development, cartilage and the
notochord express a number of similar genes as those
that encode type II and type IX collagen, aggrecan,
SOX-9 and chondromodulin, suggesting that these cells
may have conserved common physiological properties
[8–12]. These common features, taken together with
previous work, suggest that the soluble factors secreted
by notochordal cells may also confer anabolic and anti-
catabolic effects upon cartilage.
Within the spectrum of DDD, the peculiar
phenomenon of the non-chondrodystrophic canine
(NCD) is of particular importance to possible treat-
ments for OA. The NCD animal does not develop DDD
until much later in life, if at all, ostensibly due to the
persistence of notochordal cells within the NP of the
intervertebral disc (IVD) [13, 14]. In contrast, it is
widely known that humans (like chondrodystrophic
beagles and dachshunds) lose their notochordal cells
early in life and are far more prone to developing DDD
[15, 16]. A number of publications detailing the mech-
anism of action of notochordal cells have established
that these cells provide an anti-degenerative effect upon
cells within the NP, including anti-apoptotic effects
[17–19]. Furthermore, notochordal cell conditioned
medium (NCCM) has been shown to induce an upregu-
lation of anabolic/matrix protective genes such as type
II collagen, the CD44 receptor and TIMP-1, as well as
downregulation of matrix-degrading genes like matrix
metalloproteinase-3 (MMP-3) [18, 20, 21]. Furthermore,
NCCM treatment increases cell proliferation and pro-
teoglycan production, and directs degenerative IVD NP
cells towards healthier phenotypes [22, 23]. Addition-
ally, mesenchymal stem cells (MSC) treated with
NCCM produce more proteoglycan compared to con-
trol medium [23, 24].
We hypothesized that, similar to its action on NP cells,
NCCM exerts metabolic and anti-catabolic effects on ar-
ticular chondrocytes. We were interested in the possibil-
ity that soluble factors contained within NCCM could
be exploited in a chondroprotective strategy for the
treatment of osteoarthritis/cartilage injury. Therefore,
we elected to use NCCM obtained from NCD dogs to
treat human chondrocytes conditioned with pro-
inflammatory cytokines or chondrocytes obtained at the
time of total knee arthroplasty in a proof-of-principle
study. If effective, recombinant forms of the necessary
and sufficient factors contained within NCCM could be
used in a minimally invasive strategy. We have demon-
strated previously that there is considerable preservation
in genomic and proteomic sequences between canine
and human species in that we have determined the pres-
ence of connective tissue growth factor (CTGF) within
NCCM in our first proteomic analysis of NCCM, valid-
ating that the use of cross-species conditioned medium
is a valid approach [21].
Methods
Preparation of notochordal cell conditioned medium
(NCCM)
We have reported on the use of NCCM extensively in
our past publications [17, 21, 25]. In the current study,
notochordal cell-rich IVD NPs were obtained from 10
different NCD dogs within an age range of 12–18
months in collaboration with a licensed animal facility
and all practices were in accordance with the animal
care policies and ethics approval board of The University
Health Network, Toronto, Ontario, Canada. Briefly, after
humane euthanasia, the T6-L6 spinal segments were re-
moved aseptically en bloc and a wide laminectomy per-
formed separating the posterior elements from the
vertebral bodies. Next, we removed the NPs in accord-
ance with our established methods and developed
NCCM by culturing the NPs in advanced Dulbeccos’s
modified Eagle’s medium F/12 (ADMEM/F12) supple-
mented with 2 % fetal bovine serum (FBS) (v/v) and
penicillin/streptomycin (PS) (100 U/mL) [18]. We col-
lected the NCCM at 24-hour intervals for 5 days and at
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each interval the NCCM was centrifuged for 20 minutes
at 3000 g and filtered using 0.2-μm filters (Corning,
USA). Next the media were transferred to 15-mL ali-
quots and frozen at –80 C. Consistent with our estab-
lished methods once the media were collected, filtered
and centrifuged they were pooled in order to remove
any batch-to-batch variability and all culture conditions
were performed with identical conditioned medium. We
generated 2 % FBS (v/v)-supplemented ADMEM/F12 as
the control medium (ctr).
Healthy chondrocyte culture
Cartilage sample collection, and cell isolation and
expansion
In the first experiments cartilage tissue was harvested
from nine donors (18–68 years of age), from macroscop-
ically healthy-looking areas of their knee joints. Two
samples were taken from an 18-year-old man and a 68-
year-old man during diagnostic arthroscopy and seven
samples were taken from cadavers within 24 hours after
donors had deceased (age range 41–64 years). Either pa-
tients or relatives gave informed consent for tissue har-
vest. All tissue samples were minced with a scalpel into
small pieces that were then digested overnight in 0.2 %
collagenase II (300 U/mg, Worthington Biochemical
Corp, Lakewood, NJ, USA) in an orbital shaker at 37 °C.
The isolated chondrocytes were then expanded for two
passages in basal medium (BM, DMEM, 10 mM HEPES,
1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/mL
streptomycin, and 0.29 mg/mL glutamate (all from Invi-
trogen)) supplemented with 10 % FBS, 5 ng/mL fibro-
blast growth factor-2 (FGF-2) and 1 ng/mL transforming
growth factor (TGF)ß1 in a humidified incubator (37 °C,
5 % CO2, 19 % oxygen) as previously described [26].
Chondrogenic differentiation in pellets Chondrogenic
differentiation was induced by culturing the expanded
chondrocytes in pellets using defined serum-free medium
as previously described [27]. Briefly, cells were re-
suspended in chondrogenic medium (BM, 1.25 mg/mL
human serum albumin, ITS-A (Invitrogen), 10 ng/mL
TGF-ß1 (R&D Systems), and 10-7 M dexamethasone and
0.1 mM ascorbic acid 2-phosphate (Sigma-Aldrich).
Aliquots of 2.5 × 105 cells/250 μL were centrifuged at
250 g for 5 minutes in 1.5 mL screw-cap Eppendorf tubes.
Pellets were cultured for 2 weeks in a humidified incuba-
tor (37 °C, 5 % CO2, 19 % oxygen) with a change of
medium twice a week.
Inflammation and recovery cultures After 2 weeks of
culture, the pellets were harvested for baseline histological
and biochemical assessments, while the remaining were
exposed to IL-1β (Sigma, I9401) and TNF-α (Peprotech),
each at 1 ng/mL, for 72 hours. During this inflammatory
phase, pellets were cultured in chondrogenic medium de-
prived of TGF-β1 and dexamethasone. Pellets were then
harvested for analysis or cultured for 2, 7, and 14 days in
NCCM or 2 % FBS-supplemented ADMEM/F12 (ctr)
(Fig. 1).
To assess possible age-dependent differences in the re-
sponse of chondrocytes to the inflammatory factors and
post-inflammatory NCCM treatment, donors were
assigned to two arbitrary age groups: group 1, ≤55 years
of age (n = 4) and group 2, >55 years of age (n = 5).
Fig. 1 Outline of experimental approach. Human articular chondrocytes (Ch) collected from healthy and osteoarthritic (OA) cartilage tissues were
expanded in vitro and then cultured in pellets (phase I culture). Resulting tissues were then exposed to interleukin 1 beta (IL-1β) and tumor necrosis factor-
alpha (TNF-α) for 3 days (d) and then cultured for an additional 2 weeks (phase II culture) in medium containing 2 % FBS-supplemented notochordal cell
conditioned medium (NCCM) or in control medium (2 % FBS-supplemented ADMEM/F12, (CTR)). Pellets generated from OA chondrocytes were cultured in
NCCM or CTR medium without any pro-inflammatory treatment. TGF transforming growth factor
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Osteoarthritic chondrocyte culture
Based on the findings generated with the healthy chondro-
cytes, in a second experiment we investigated the effects
of NCCM on chondrocytes obtained from six patients
(ages 60–82 years, all female), who suffered from end-
stage OA and were undergoing total knee arthroplasty.
Within 2 hours of tissue harvest, pieces of grossly visible
degraded osteoarthritic cartilage were collected and dir-
ectly processed as described above. Isolated OA chondro-
cytes were also expanded and chondrogenically cultured
as described for the healthy chondrocytes. After 2 weeks
of chondrogenic differentiation, baseline pellets were col-
lected for histological, immunohistochemical and bio-
chemical analyses. Hereafter, the remaining pellets were
directly cultured in NCCM or control medium. Medium
was changed twice a week and pellets were harvested at 2,
7, and 14 days (see Fig. 1 for the experimental plan). Cul-
ture medium was also collected from baseline pellets and
pellets cultured in control and NCCM medium, to quan-
tify the amounts of released cytokines.
In order to assess whether the soluble glycosaminogly-
cans (GAGs) contained in NCCM could have served as
active factors, chondrogenic pellets obtained from one of
the NCCM-responder donors were also cultured with
control medium supplemented with 1 mg/mL chondro-
itin sulphate (Sigma, CS9819) for 2 weeks; the amount
of chondroitin sulphate used corresponded to the con-
centration of GAG measured in the basal NCCM
medium used in this study).
Analytical methods
Biochemical analysis
To measure the amounts of sulfated GAG and DNA,
pellets (n = 3) from each group and condition were
digested with Proteinase K (0.5 ml of 1 mg/mL protease
K in 50 mM Tris with 1 mM EDTA, 1 mM iodoaceta-
mide, and 10 mg/mL pepstatin-A) for 15 hours at 56 °C.
The GAG content was measured spectrophotometrically
after reaction with dimethylmethylene blue and chon-
droitin sulfate as a standard (Sigma, C8529), using the
Blyscan color assay kit (Biocolor Ltd, Carrickfergus, UK).
For further analysis the mean amount of GAG for each
condition was normalized to the corresponding mean
amount of DNA, which was measured spectrofluorome-
trically using the CyQUANT cell proliferation assay kit
(Molecular Probes, Eugene, OR, USA), with bovine
DNA as a standard. GAG and DNA content is reported
as μg GAG/μg DNA for samples and supernatants or
normalized to baseline values, respectively. Additionally,
GAG was also quantified in the basal NCCM medium.
Histologic and immunohistochemical analysis
Pellets (n = 2) for each condition were fixed in 4 % for-
malin for 24 hours, washed with PBS, and then
embedded in paraffin blocks. For (immuno-) histological
staining the samples were sectioned at a thickness of
5 μm. Sections were then stained with Safranin O for
sulfated GAGs or processed for more detailed immuno-
histochemical analyses with antibodies against collagen
type I collagen (mouse-anti-human, Clone I-8H5, MP
Biomedicals) and type II collagen (mouse-anti-human,
clone II-4 CII, MP Biomedicals, Santa Ana, CA, USA).
Western blotting
The expression of anabolic (SOX-9, HAPLN1, and fibro-
modulin), and catabolic proteins (MMP-3, MMP-13, and
COX-2) in either NCCM-treated or Ctr-treated pellets
was detected by western blot with β-actin used as a load-
ing control. Total protein was extracted from OA pellets
of every donor for each condition. We used the Pierce
BCA Protein Assay Kit (Thermo Scientific, Rockwood, IL,
USA) together with radioimmunoprecipitation assay
(RIPA) lysis buffer for protein extraction and measure-
ment of the protein concentration according to the
manufacturer’s instructions. Results were then read
with a Perkin Elmer Victor3 Multilabel Counter (model
1420). Proteins were resolved on 10 % sodium dodecyl
sulphate-polyacrylamide gels (SDS-PAGE) and then
electro-transferred onto polyvinyledendifluroide (PVDF)
membranes (BioRad, Hercules, CA, USA). SDS-PAGE gels
were then transferred to nitrocellulose membrane in
transfer buffer (BioRad) containing 20 % methanol. Mem-
branes were washed with TBS-T (TBS, 0.1 M, pH = 7.4;
0.1 % Tween 20, Bioshop) and then blocked with 5 %
non-fat milk extract in a TBS blocking buffer for 1 hour in
an orbital shaker at room temperature. We then incubated
the membranes with the primary antibody of each protein
of interest (see Additional file 1). The next morning,
membranes were washed three times with Tween 20
(0.1 %)-TBS-T for 5 minutes each in an orbital shaker and
thereafter, incubated with goat anti-rabbit IgG (H + L)-
HRP conjugate (Bio-Rad cat. 170-6515), goat anti-mouse
IgG(H + L)-HRP conjugate (Bio-Rad cat. 170-6516) and
rabbit anti-goat F(AB)2 HRP XADs (NOVEX cat.
A24452) secondary antibodies, respectively, diluted at an
appropriate dilution in 1 % non-fat powdered milk for
1 hour at room temperature. Conjugates were matched
with the appropriate antibody, i.e., rabbit polyclonal anti-
Sox9 (Abcam cat. ab71762) 1:200 was matched with goat
anti-rabbit IgG conjugate, etc. Blots were then washed
three times with Tween 20 (0.1 %)-TBS. Signals were visu-
alized by exposing the membranes to enhanced chemilu-
minescence (ECL) reagent (Biorad) according to the
manufacturer’s instructions. Densitometry values were cal-
culated for each band using ImageJ (National Institute of
Health). Results of western blot analysis are presented as
fold-change for pellets after 14 days treatment (NCCM or
Ctr) compared to baseline.
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Enzyme-linked immunosorbent assay
We determined differential OA chondrocyte pellet cyto-
kine secretion using supernatants obtained from two
representative responder donors using the multi-analyte
cytokine profiling ELISA kit according to the manufac-
turer’s instruction (Qiagen, ML, USA) evaluating the ex-
pression of IL-6 and IL-8 in particular. We performed
each experiment in triplicate.
Statistical analysis
Statistical evaluation was performed using SPSS 21
(IBM, Armonk, NY, USA). Values are presented as mean
with corresponding standard deviation (SD) or as nor-
malized to baseline values. Differences between experi-
mental groups were assessed using the Mann-Whitney
U test for non-parametric samples. P values <0.05 were
considered significant.
Results
NCCM restores post-inflammation GAG production by
healthy articular chondrocytes only from older donors
Cells from the two age groups (group 1 ≤55 years, group
2 >55 years of age) proliferated at a similar rate (number
of doublings/day 0.52 ± 0.12 and 0.45 ± 0.08, respectively;
p > 0.05). The DNA content of pellets generated from cells
of individuals within the two age groups did not signifi-
cantly vary after the treatment with inflammatory factors
or during the subsequent phase II culture in control or
NCCM-medium (Fig. 2a). However, the GAG/DNA con-
tent of the pellets decreased significantly following IL-1β
and TNF-α exposure (by 1.7-fold and 1.9-fold, respect-
ively) for group 1 (≤55 years of age), and group 2
(>55 years of age). The extent of GAG recovery varied in
the two groups. In group 1 the GAG/DNA content of pel-
lets remained lower (as compared to baseline) beginning
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Fig. 2 Biochemical analyses of pellets generated with healthy chondrocytes. a DNA and b sulfated glycosaminoglycan (GAG) content of chondrocyte
pellets normalized to the DNA content (GAG/DNA). Data are expressed as fold-change in patients ≤55 years of age (left) or >55 years of age (right). All
pellets were treated after the phase I culture (baseline) with the inflammatory treatment (IL-1β + TNF) and after 2, 7, and 14 additional days of culture
in control (ctr) medium or notochordal cell conditioned medium (NCCM) (see Fig. 1 for experimental design). Data are means ± SD (n indicates the
number of cartilage donors; for each donor two to three experimental replicates were analyzed); *p < 0.05 from baseline; °p < 0.05 from ctr (same
recovery time). Treatment with NCCM does not result in any significant increase in DNA in either group of patients (a). In chondrocyte pellets from
patients >55 years of age, NCCM treatment results in a significant increase in GAG/DNA content, returning to baseline levels at 14 days of culture;
°p < 0.05 (b)
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below baseline by day 7; however, it did not increase sig-
nificantly by day 14 (Fig. 2b). There were no significant
differences in GAG/DNA content in Ctr-treated or
NCCM-treated pellets during any of the phase II cultures
(Fig. 1b (≤55 years of age)). On the other hand, although
pellets treated with control medium in group 2 (>55 years
of age) also had lower GAG/DNA content for the entire
phase II culture (after treatment with pro-inflammatory
mediators) (Fig. 2b), by day 14 the GAG/DNA content of
NCCM-treated pellets had increased significantly to re-
turn to baseline levels (Fig. 2b).
These initial results indicate that while chondrocyte pel-
lets from young individuals have an intrinsic capacity to re-
cover following an inflammatory insult, NCCM confers
such recovery upon tissue pellets of chondrocytes from
older donors. As the articular cartilage from patients over
the age of 60 years, even if appearing macroscopically
healthy, could present pre-osteoarthritic changes, we chose
to investigate the ability of NCCM to rescue articular chon-
drocytes obtained from patients with end-stage OA.
NCCM upregulates cartilage matrix production in OA
chondrocytes
After 14 days of pellet culture the DNA content of pel-
lets in the Ctr group was lower (1.4-fold, p < 0.05) than
the baseline content and remained comparable to base-
line levels in pellets cultured with NCCM at all the in-
vestigated time points (Fig. 3a). The GAG/DNA content
of Ctr-cultured pellets slightly decreased over time and
remained largely constant, such that at the last time
point it was 1.8-fold lower than at baseline. In contrast,
OA chondrocyte pellet cultures treated with NCCM had
drastically enhanced accumulation of GAG/DNA, such
that by day 14, the accumulated GAG/DNA content was
1.8-fold higher (p < 0.05) than at baseline (Fig. 3a).
We thus compared the GAG/DNA content of pellets
generated by healthy chondrocytes (from donors >
55 years) with those of pellets generated from OA chon-
drocytes. At the end of culture phase II, OA chondro-
cytes cultured with NCCM accumulated GAG at a level
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Fig. 3 Biochemical analyses of pellets generated with osteoarthritic (OA) chondrocytes. a DNA contents (left) and sulfated glycosaminoglycan
(GAG) contents normalized to the DNA content (GAG/DNA) (right) of pellets after the phase I culture (baseline) and after 2, 7, and 14 additional
days of culture in control (ctr) medium or notochordal cell conditioned medium (NCCM) (see Fig. 1 for the experimental design). Levels are
expressed as fold-difference from those measured at baseline. Data are means ± SD (n indicates the number of cartilage donors; for each donor
two to three experimental replicates were analyzed); *p < 0.05 from baseline; °p < 0.05 from ctr (same culture time). b GAG/DNA content of pellets
generated by healthy chondrocytes at baseline (n = 4, same as those in Fig. 2, > 55 years of age) and OA chondrocytes after phase II culture in
ctr medium and NCCM; *significant difference at p < 0.05; n.s. difference not significant
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whereas the GAG content of Ctr-cultured pellets was in-
stead 2.6-fold lower (p < 0.05) (Fig. 3b).
Histological analyses confirmed the biochemical re-
sults. The intensity of Safranin-O and type II collagen
staining decreased in pellets after 7 days of culture in
Ctr medium and become almost undetectable after
14 days. However, Safranin-O and collagen type II stain-
ing in pellets cultured for 14 days with NCCM were
higher than those at baseline (Fig. 4).
The anabolic effects of NCCM are not mediated by
chondroitin sulfate
We wondered if the aforementioned anabolic effects of
NCCM were merely due to the chondroitin sulfate (CS)
contained within the NCCM. Therefore, we exposed
chondrocyte pellets obtained from one of the NCCM-
responsive OA donors (82 years of age, female) to 1 mg/
mL CS (i.e., equivalent CS concentration as in the
NCCM used in the previous experiments) for 14 days
and assessed them biochemically. The GAG/DNA con-
tent of pellets cultured for 14 days in CS decreased 2.5-
fold compared to baseline, whereas the GAG/DNA con-
tent increased in pellets cultured with NCCM (Table 1).
NCCM enhances the production of anabolic factors and
reduces the production of catabolic mediators in OA
chondrocytes
We analyzed NCCM and control-cultured pellets from
OA chondrocytes using western blotting methods to
quantitatively assess differences in proteins that are im-
portant in cartilage anabolism/homeostasis and catabol-
ism/degradation. NCCM significantly enhanced the
levels of HAPLN1, fibromodulin and the master chron-
drogenic regulator SOX-9 (2.1-fold, 1.8-fold, and 2.9-fold
B C 


























Fig. 4 Histological and immunohistochemical characterizations of pellets generated by osteoarthritic chondrocytes. a Safranin-O staining of baseline pellets
and pellets after 2, 7, and 14 additional days of culture in control (CTR) medium or notochordal cell conditioned medium (NCCM). There is a clear increase
in Safranin-O with NCCM treatment at 14 days of culture. Collagen type II (b) and collagen type I (c) immunostochemical staining of representative pellets
after 14 days phase II culture in CTR medium or NCCM (see Fig. 1 for the experimental design). Bars= 100 μm. As with the Safranin-O staining, 14 days of
NCCM culture induces a marked increase in collagen type II staining with no difference in type I collagen
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higher, respectively, after NCCM treatment vs baseline)
but remained unchanged in the Ctr group (Fig. 5a). Fur-
thermore, NCCM significantly downregulated the major
catabolic/degradative mediators MMP-3, MMP-13, and
COX-2 (4.2-fold, 2.8-fold, and 2.7-fold, respectively)
(Fig. 5b). On the other hand, in control cultures MMP-3
and COX-2 expression remained largely at baseline
levels, whereas MMP-13 increased (2.0-fold, p < 0.05) in
Ctr-cultured pellets (Fig. 5b). Representative western
blots are shown in Fig. 5c).
NCCM-treated chondrocyte pellets decrease the secretion
of pro-inflammatory cytokines
We evaluated the secretion of a number of cytokines by
pellet cultures obtained from cells of two patients with
OA (donor 1, female, 73 years of age and donor 2, fe-
male, 82 years of age) after 14 days of phase II culture in
NCCM and control medium using the SABiosciences
multi-analyte cytokine ELISA SABiosciences kit (Qiagen,
ML, USA). We found that in both cases, treatment with
NCCM significantly reduced the secretion of IL-6 and
IL-8 in pellet cultures obtained from end-stage OA cartil-
age, whereas control treatment did not have any effect
(Fig. 6).
Discussion
Here we report for the first time, that NCCM has a chon-
droprotective/regenerative effect upon human articular
chondrocytes and that these effects were age and disease
dependent. NCCM treatment restored OA chondrocyte
cartilage matrix production to healthy chondrocyte base-
line levels, significantly counteracted the production of
potent pro-inflammatory cytokines, and suppressed the
secretion of key pro-inflammatory cytokines.
Osteoarthritis is a multi-factorial disease process driven
by the master regulators of cellular/ECM destruction, IL-
Table 1 Comparison of GAG/DNA accumulation within pellets
treated with CTR, Chondroitinsulfate or NCCM medium
GAG/DNA pellets (μg/μg)
Baseline 12.1 ± 1.4
14 days of CTR 3.7 ± 1.9
14 days of CS 4.8 ± 0.3
14 days of NCCM 13.4 ± 5.8
Values are mean ± SD. Control (CTR) media comprised 2 % FBS-supplemented
advanced DMEM/F-12. The chondroitin sulfate (CS) medium comprised Ctr
medium supplemented with 1 mg/mL CS. NCCM was supplemented with 2 %
FBS. The accumulation of GAG/DNA in pellets treated with NCCM was clearly
superior to CTR and CS, demonstrating that the effects of NCCM are not due
to CS. GAG glycosaminoglycan
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Fig. 5 Western blot analyses of pellets generated by osteoarthritic (OA) chondrocytes. Data representative of five independent samples of notochordal cell
conditioned medium (NCCM)-treated human OA chondrocyte pellets at 14 days of culture compared to controls (CTR). Data are fold-changes normalized
to baseline values. a Normalized expression of anabolic proteins. b Normalized expression of catabolic proteins. Representative blots (one of five samples)
are shown (c). NCCM significantly increases the levels of anabolic extracellular matrix proteins and the master chrondrogenic regulator sex determining
region Y box 9 (SOX9), compared to CTR treatment; *p< 0.05). NCCM significantly decreases the levels of the matrix-degrading matrix metalloproteinase-3
(MMP-3) and MMP-13, and the pro-inflammatory enzyme cyclooxygenase-2 (COX2); *p< 0.05. HAPLN hyaluronic acid link protein
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1β and TNFα, pro-inflammatory molecules such as the
COX-2-dependent cartilage-destructive enzyme prosta-
glandin E2 (PGE2), IL-6, IL-8, and the ECM-degrading en-
zymes such as the MMPs. Increased levels of PGE2 act in
a positive feedback loop to promote the synthesis of IL-
1β, TNFα, IL-6, and IL-8, resulting in a self-propelling
autocrine/paracrine-mediated inflammatory process [28].
The action of the inflammatory cytokines such as IL-1β,
IL-6, and IL-8 decreases the synthesis of vital ECM mole-
cules such as proteoglycans and type II collagen, thereby
diminishing the hydrophilic properties of the ECM leading
to further degradation [28–31]. It has been shown that IL-
6 correlates with worsening osteoarthritic lesions on
radiographs and that IL-6 and IL-8 potentiate the pro-
inflammatory action of IL-1β [32]. Similarly, it has been
shown that bulging/herniated IVDs express high levels of
these pro-inflammatory cytokines and that higher levels of
IL-6 and IL-8 within these tissues correlate with increas-
ing back pain suggesting that these two cytokines share
commonality in disease progression and underlying symp-
tomatology [32].
An effective biologic therapy to treat OA would neces-
sarily need to inhibit catabolism, increase anabolism, and
interfere with the pro-inflammatory milieu present in the
target tissue. Contemporary approaches to treating OA
employ orally administered analgesic or anti-inflammatory
medication and/or intra-articular injections (usually of a
steroid combination) for single joints [33]. The injection
of hyaluronic acid and platelet-rich plasma (PRP) has also
been attempted; however, the results have been rather dis-
appointing as such treatment only provided short-term
symptom relief, if at all [34–37]. However, to date, no
intervention has been found to have the ability to influ-
ence the biology of degenerative joint disease, and thus,
the notion of chondroprotection, whereby factors deliv-
ered to cartilage that may mediate its degeneration, is an
attractive therapeutic goal and would be a major break-
through in the treatment of OA.
To this end, lessons learned with respect to noto-
chordal cell interaction within the IVD could be applied
to the development of biologically based anti-OA thera-
peutic agents. We (WME and AM) have previously re-
ported that NCCM confers anti-apoptotic, pro-anabolic
and anti-catabolic effects upon IVD NP cells [17–20].
Although we do not report apoptotic signaling here, it is
clear that NCCM antagonizes the inflammatory cascade,
suppresses catabolism, and confers anabolic effects upon
vital ECM molecules. It may be that by suppressing the
levels of pro-inflammatory cytokines and enzymes,
NCCM might enable chondrocytes to restore homeo-
static regulation. Interestingly we noted a more robust
response to NCCM by osteoarthric vs healthy chondro-
cytes. While the effects of NCCM might be more effect-
ive within the inflammatory milieu, it could be that in
addition to its anti-inflammatory activity, the bioactive
factors within NCCM could also target specific subpop-
ulations of chondrogenic progenitor cells known to be
present with advancing OA [38, 39]. The drug Diacerein
has been reported to antagonize pro-inflammatory
changes in chondrocytes in vitro through the suppres-
sion of MMP1 and IL-8 activity, suggesting its potential
utility as a treatment for OA [30]. However, there is no
evidence that this drug is capable of inducing the broad
range of anti-catabolic and pro-anabolic effects neces-
sary for an effective anti-OA intervention. This is in
contrast to the chondroprotective and regenerative ef-
fects conferred upon human chondrocytes by NCCM in
our study, including the re-differentiation of end-stage
OA chondrocytes to a healthy phenotype.
As with all investigations, there are some limitations
to this study. For example, we studied the response of






















Donor 1 Donor 2 
Cytokine expression profile in culture supernatants
Fig. 6 Cytokine ELISA of supernatants from pellets generated by osteoarthritic chondrocytes. These data indicate that notochordal cell conditioned
medium (NCCM)-treated chondrocyte pellet cultures secrete significantly less IL-6 and IL-8 than control (ctr) cultures (donor 1, female, 73 years of age;
donor 2, female, 82 years of age); *p < 0.05 compared to ctr; **p < 0.01 compared to ctr
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with NCCM but it might be that cells within a native tis-
sue may exhibit different responses. However, we pre-
ferred to use this in vitro method because it allows
better calculation of new matrix deposition as compared
to the organ culture model. It is important to illustrate
that the OA cartilage obtained in this study was ob-
tained from joints that had not been injected with ste-
roids for at least 4–6 months, providing a robust
washout period that would account for any transient
changes in response to treatment. Even so, all samples
were subjected to the same no-treatment controls and
the responses for all donor cells were very consistent,
dismissing the likelihood of biological variability associ-
ated with any exogenous intervention.
Conclusions
NCCM treatment restored OA chondrocyte cartilage
matrix production to healthy chondrocyte baseline levels,
significantly counteracts the production of potent pro-
inflammatory cytokines, suppressed the secretion of key
pro-inflammatory cytokines and upregulated the master
chondrogenic regulator SOX9. The precise signaling
mechanisms whereby NCCM confers pro-anabolic, anti-
catabolic, and anti-inflammatory effects remain to be de-
termined. However, these novel observations open the
door to the development of an entirely novel molecular
therapy for the treatment of osteoarthritis and chondro-
protection, utilizing the necessary and sufficient factors se-
creted by the notochordal cell-rich IVD NP.
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